Citations

Showing 10 of 108104 citations.

Standardizing the clinical and dermatoscopic exam for patients with afro‐textured hair and scarring alopecia: A scoping review and clinical guide
Adotama, Prince , Sicco, Kristen Lo , London, Ashley O., Ederaine, Sophia A. , Rotemberg, Veronica , Mayo, Tiffany , Shapiro, Jerry

Mayo Clinic

JEADV Clinical Practice | February 14, 2022 | Volume: 1 | Issue: 1 | Pages: 31-37

10.1002/jvc2.13 Get It

AbstractAlopecia is one of the most common reasons for a dermatology visit among Black patients. Patients with concomitant afro‐textured hair and scarring alopecias are often subjected to delays in diagnosis and treatment. Race‐discordant physicians may find the examination of scarring alopecias in ethnic hair to be daunting. Herein we present a standardized approach to evaluating the hair and scalp in afro‐textured alopecia patients in the hopes of providing a framework and guide for the proper clinical assessment of these patients. This guide focuses on common scarring alopecias specific to this ethnic population including traction alopecia, central centrifugal alopecia, frontal fibrosing alopecia and lichen planopilaris.
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia
Advani, Anjali S. , Moseley, Anna , O'Dwyer, Kristen M., Wood, Brent L. , Fang, Min, Wieduwilt, Matthew J. , Aldoss, Ibrahim, Park, Jae H., Klisovic, Rebecca B. , Baer, Maria R., Bhave, Rupali R., Harvey, Richard C., Willman, Cheryl L., Litzow, Mark R. , Stone, Richard M. , Stock, Wendy , Othus, Megan , Litzow, Mark R. , Stone, Richard M , Sharon, Elad , Erba, Harry Paul , Wieduwilt, Matthew J , Advani, Anjali S , Wood, Brent L , Moseley, Anna , O'Dwyer, Kristen M., Fang, Min, Aldoss, Ibrahim, Park, Jae H., Klisovic, Rebecca B. , Baer, Maria R., Bhave, Rupali R., Harvey, Richard C., Willman, Cheryl L.

Mayo Clinic

Journal of Clinical Oncology | February 14, 2022 | Volume: 40 | Issue: 14 | Pages: 1574-1582

10.1200/jco.21.01766 | PMID 35157496 Get It

PURPOSE Chemotherapy outcomes in older patients with Philadelphia (Ph) chromosome–negative B-acute lymphoblastic leukemia (ALL) are very poor. Here, we evaluated blinatumomab as induction and consolidation therapy followed by prednisone, vincristine, 6-mercaptopurine, and methotrexate (POMP) maintenance chemotherapy in this patient population. PATIENTS AND METHODS Patients were treated at National Clinical Trial Network sites. Eligibility criteria included age ≥ 65 years and newly diagnosed Ph chromosome–negative B-ALL. Patients received blinatumomab as induction for one-two cycles until attainment of response (complete remission (CR) and CR with incomplete count recovery). Patients then received three cycles of consolidation with blinatumomab followed by 18 months of POMP maintenance chemotherapy. Eight doses of intrathecal methotrexate were administered as central nervous system prophylaxis. RESULTS Twenty-nine eligible patients were enrolled. The median age was 75 years, and the median bone marrow blast count at diagnosis was 87%. Cytogenetic risk was poor in 10 patients (34%), and five of 14 patients (36%) tested had the Ph-like ALL gene signature. Nineteen patients (66%; 95% CI, 46 to 82) achieved CR. Kaplan-Meier 3-year disease-free survival and overall survival estimates were 37% (95% CI, 17 to 57) and 37% (95% CI, 20 to 55), respectively. CONCLUSION Blinatumomab was well tolerated and effective in the treatment of older patients with newly diagnosed Ph chromosome–negative B-ALL, including patients with poor-risk cytogenetics. The 3-year disease-free survival and overall survival results are encouraging and suggest that this approach should be further explored.
TFAM-Dependent Mitochondrial Metabolism Is Required for Alveolar Macrophage Maintenance and Homeostasis
Gao, Xiaochen , Wu, Yue , Li, Chaofan , Tang, Jinyi , Sun, Jie , Wu, Y , Li, Chaofan , Sun, Jie , Tang, J , Zhu, Bibo , Zhou, Xian

Mayo Clinic

The Journal of Immunology | February 14, 2022 | Volume: 208 | Issue: 6 | Pages: 1456-1466

10.4049/jimmunol.2100741 | PMID 35165165 Get It

Abstract Alveolar macrophages (AMs) are major lung tissue-resident macrophages capable of proliferating and self-renewal in situ. AMs are vital in pulmonary antimicrobial immunity and surfactant clearance. The mechanisms regulating AM compartment formation and maintenance remain to be fully elucidated currently. In this study, we have explored the roles of mitochondrial transcription factor A (TFAM)–mediated mitochondrial fitness and metabolism in regulating AM formation and function. We found that TFAM deficiency in mice resulted in significantly reduced AM numbers and impaired AM maturation in vivo. TFAM deficiency was not required for the generation of AM precursors nor the differentiation of AM precursors into AMs, but was critical for the maintenance of AM compartment. Mechanistically, TFAM deficiency diminished gene programs associated with AM proliferation and self-renewal and promoted the expression of inflammatory genes in AMs. We further showed that TFAM-mediated AM compartment impairment resulted in defective clearance of cellular debris and surfactant in the lung and increased the host susceptibility to severe influenza virus infection. Finally, we found that influenza virus infection in AMs led to impaired TFAM expression and diminished mitochondrial fitness and metabolism. Thus, our data have established the critical function of TFAM-mediated mitochondrial metabolism in AM maintenance and function.
Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression
Moderie, Christophe , Núñez, Nicolás A. , Fielding, Allan, Comai, Stefano , Gobbi, Gabriella , Nunez, Nicolas

Mayo Clinic

International Journal of Neuropsychopharmacology | February 14, 2022 | Volume: 25 | Issue: 6 | Pages: 479-488

10.1093/ijnp/pyac017 | PMID 35167671 Get It

AbstractBackgroundWomen are nearly twice as likely as men to suffer from major depressive disorder. Yet, there is a dearth of studies comparing the clinical outcomes of women and men with treatment-resistant depression (TRD) treated with similar augmentation strategies. We aimed to evaluate the effects of the augmentation strategies in women and men at the McGill University Health Center.MethodsWe reviewed health records of 76 patients (42 women, 34 men) with TRD, treated with augmentation strategies including antidepressants (AD) with mood stabilizers (AD+MS), antipsychotics (AD+AP), or in combination (AD+AP+MS). Clinical outcomes were determined by comparing changes on the 17-item Hamilton Depression Rating Scale (HAMD-17), Montgomery-Åsberg Depression Rating Scale (MADRS), Quick Inventory of Depressive Symptomatology (QIDS-C16), and Clinical Global Impression rating scale (CGI-S) at the beginning and after 3 months of an unchanged treatment. Changes in individual items of the HAMD-17 were also compared between the groups.ResultsWomen and men improved from beginning to 3 months on all scales (P < .001, η p2 ≥ 0.68). There was also a significant sex × time interaction for all scales (P < .05, η p2 ≥ 0.06), reflecting a greater improvement in women compared with men. Specifically, women exhibited greater improvement in early (P = .03, η p2 = 0.08) and middle-of-the-night insomnia (P = .01, η p2 = 0.09) as well as psychomotor retardation (P < .001 η p2 = 0.16) and psychic (P = .02, η p2 = 0.07) and somatic anxiety (P = .01, η p2 = 0.10).ConclusionsThe combination of AD+AP/MS generates a significantly greater clinical response in women compared with men with TRD, supporting the existence of distinct pharmacological profiles between sexes in our sample. Moreover, they emphasize the benefit of augmentation strategies in women, underscoring the benefit of addressing symptoms such as insomnia and anxiety with AP and MS.
Impact of the COVID-19 Pandemic on Resident Physician Clinical and Educational Work Hours at a Large Sponsoring Institution
Lund, Sarah , Hinduja, Pranav , Doherty, Julie, Rose, Steven H., Stulak, John M., Rivera, Mariela , Rose, Steven

Mayo Clinic

Journal of Graduate Medical Education | February 14, 2022 | Volume: 14 | Issue: 1 | Pages: 64-70

10.4300/jgme-d-21-00295.1 | PMID 35222823 Get It

ABSTRACT Background The COVID-19 pandemic affected graduate medical education (GME) by decreasing elective procedures and disrupting didactic learning activities in 2020. Editorials have hypothesized that resident physicians worked fewer hours, therefore losing valuable experience, but we are not aware of studies that have objectively assessed changes in hours worked. Objective This study aims to identify differences secondary to the COVID-19 pandemic in resident work hours across all specialties at 3 geographically dispersed, integrated academic hospitals in a large sponsoring institution. Methods We obtained de-identified work hour data from all residency programs at Mayo Clinic in Arizona, Florida, and Minnesota. Resident work hours were compared between 2020 and 2019 from March to May. Results Work hours for 1149 and 1118 residents during the pandemic and control periods respectively were compared. Decreases in resident work hours were seen, with the largest decrease demonstrated in April 2020 when 19 of 43 programs demonstrated significantly decreased work hours. Residents worked more hours from home in April 2020 compared to the previous year (Arizona: mean 1 hour in 2019 vs 5.2 hours in 2020, P<.001; Florida: mean 0.7 hour in 2019 vs 6.5 hours in 2020, P<.001; Minnesota: mean 0.8 hour in 2019 vs 10.2 hours in 2020, P<.001). Conclusions The COVID-19 pandemic was associated with a decrease in work hours in some, but not all, specialties. The decrease in on-site work was only partially offset by an increased number of hours worked from home.
Combined Endoscopic Endonasal and Exoscope-Assisted Open Transbasal Resection of Sinonasal Squamous Cell Carcinoma: 2-Dimensional Operative Video
Vakharia, Kunal V., Naylor, Ryan M., Choby, Garret, Gompel, Jamie J. Van, Vakharia, Kunal , Naylor, Ryan M., Choby, Garret, Gompel, Jamie J. Van

Mayo Clinic

Operative Neurosurgery | February 14, 2022 | Volume: 22 | Issue: 4 | Pages: e173-e173

10.1227/ons.0000000000000103 | PMID 35156941 Get It

Ginseng for the Treatment of Chronic Fatigue Syndrome: A Systematic Review of Clinical Studies
Yang, Juan , Shin, Kyung-Min, Dabrh, Abd Moain Abu , Bierle, Dennis M, Zhou, Xuan, Bauer, Brent A. , Mohabbat, Arya B, Abu Dabrh, Abd Moain , Yang, Juan , Shin, Kyung-Min, Bierle, Dennis M, Zhou, Xuan, Bauer, Brent A , Mohabbat, Arya B

Mayo Clinic

Global Advances in Health and Medicine | February 14, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2164957x221079790 | PMID 35186446 Get It

Background Chronic fatigue syndrome (CFS) is a complex and often disabling chronic condition emerging worldwide, with no curative or definitive therapy yet identified. Ginseng has been widely used to treat fatigue in other patient groups and conditions; however, a systematic review focusing solely on the impact of ginseng on fatigue in patients with CFS has not been performed. Objective This study aimed to assess the current state of evidence regarding ginseng for CFS. Methods Multiple databases were searched from inception to October 2020. All data was extracted independently and in duplicates. Outcomes of interest included the effectiveness and safety of ginseng in patients with CFS. Results 2 studies enrolling 68 patients were deemed eligible, including one randomized clinical trial and one prospective observational study. The certainty of evidence in the effectiveness outcome was low and moderate from both studies, while the safety evidence was very low as reported from one study. Conclusion Study findings highlight a potential benefit of ginseng therapy in the treatment of CFS. However, we are not able to draw firm conclusions due to limited clinical studies. The paucity of data warrants limited confidence. There is a need for future rigorous studies to provide further evidence.
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases
Singh, Amritpal , Al‐Kali, Aref , Begna, Kebede H. , Litzow, Mark R. , Larsen, Jeremy T. , Sher, Taimur , Abdelmagid, Maymona, Farrukh, Faiqa, Reichard, Kaaren K. , Gangat, Naseema , Pardanani, Animesh , Tefferi, Ayalew , Abdelmagid, Maymona G

Mayo Clinic

American Journal of Hematology | February 14, 2022 | Volume: 97 | Issue: 5 | Pages: 630-637

10.1002/ajh.26498 | PMID 35156231 Get It

AbstractWe retrospectively examined our experience with midostaurin therapy in 33 consecutive patients (median age 68 years; 58% females) with advanced systemic mastocytosis (adv‐SM): aggressive SM (ASM; n = 17), SM associated with another hematologic neoplasm (SM‐AHN; n = 14) and mast cell leukemia (MCL; n = 2). KITD816V mutation was detected in 84% of the patients and C findings in 91%. Eleven (33%) patients were previously treated with other cytoreductive drugs, including cladribine (n = 4) and imatinib (n = 3). Median time from diagnosis to initiation of midostaurin therapy was 2.2 months (range 0.3–41). Using modified valent criteria, overall response was 42% (53% ASM, 29% SM‐AHN, 50% MCL; p = .22), all classified as being major. Responses included ≥50% reduction in bone marrow mast cells in 40% and normalization of serum tryptase in 29%, of evaluated cases. After a median follow‐up of 14.6 months from initiation of midostaurin therapy, 7 (21%) deaths, 1 (3%) leukemic progression, and 18 (55%) treatment discontinuations were documented; median duration of midostaurin treatment was 7.9 months (range 0.5–123) and response duration 21.5 months (range 2.9–123). Most frequent side effect was gastrointestinal (51%) while grade 3/4 neutropenia or thrombocytopenia occurred in 12% of patients. Response to treatment was not predicted by KIT mutation (p = .67) or exposure to prior cytoreductive therapy (p = .44). Median survival was longer in midostaurin responders but not significantly (median 26.5 vs. 16 months; p = .15). Findings from the current study are broadly consistent with previously published clinical trial observations.
Improving Transitions in Care for Patients and Family Caregivers Living in Rural and Underserved Areas: The Caregiver Advise, Record, Enable (CARE) Act
Griffin, Joan M. , Bangerter, Lauren R. , Holland, Diane E. , Vanderboom, Catherine E., Ingram, Cory , Wild, Ellen, Dose, Ann Marie , Stiles, Carole, Thompson, Virginia H., Wild, Ellen M, Griffin, Joan M , Kaufman, Brystana G.

Mayo Clinic

Journal of Aging & Social Policy | February 14, 2022 | Volume: 36 | Issue: 4 | Pages: 581-588

10.1080/08959420.2022.2029272 | PMID 35156557 Get It

The Burden of Vaccine-preventable Diseases in Patients With Inflammatory Bowel Disease
Kröner, Paul T., Picco, Michael F., Cangemi, John R., Hayney, Mary S., Farraye, Francis A., Caldera, Freddy, Kröner, Paul T., Picco, Michael F., Cangemi, John R., Hayney, Mary S., Farraye, Francis A., Caldera, Freddy

Mayo Clinic

Journal of Clinical Gastroenterology | February 14, 2022 | Volume: 56 | Issue: 9 | Pages: 798-804

10.1097/mcg.0000000000001635 | PMID 35152238 Get It

Background: Patients with inflammatory bowel disease (IBD) are at an increased risk of infections, including vaccine-preventable diseases (VPDs). The aim of this study was to explore the inpatient prevalence of VPD in patients with IBD, as well as inpatient outcomes. Methods: Retrospective study using the 2013-2017 Nationwide Inpatient Sample databases. All patients 18 years of age or older with International Classification of Diseases, Ninth and 10th Revisions, Clinical Modification (ICD-9/10 CM) codes for IBD were included, as well as patients with VPDs as a principal diagnostic code. The primary outcome was the occurrence and odds of VPD in patients with IBD compared with patients with no IBD. Secondary outcomes were inpatient mortality, morbidity, and economic burden compared with patients with IBD and non–vaccine-preventable infections (VPIs). Multivariate regression yielded adjusted odds ratios. Results: Of 1,622,245 (0.9%) patients with a diagnosis of IBD, 3560 (0.2%) had associated VPDs, while 131,150 patients had non-VPI (8.1%). The most common VPDs were influenza, herpes zoster (HZ), pneumococcal pneumonia, and varicella. Only HZ and varicella had increased odds of occurrence in patients with IBD of all ages. Patients with IBD 65 years of age or older had increased odds of VPD compared with patients under 65 years. Patients with IBD and associated VPD had higher odds of intensive care unit stay, systemic inflammatory response syndrome, and multiorgan failure compared with patients with IBD and non-VPI. Conclusions: VPDs represent a clinically relevant cause of infectious disease-related hospital admissions in patients with IBD. Patients with IBD are at increased risk for hospitalization due to HZ and varicella. Those hospitalized for VPD have higher morbidity compared with patients with IBD and non-VPI. These findings echo the importance of instituting optimal immunization schedules in patients with IBD, particularly in patients 65 years or older.